Mucinous Carcinoma of the Breast in Comparison with Invasive Ductal Carcinoma: Clinicopathologic Characteristics and Prognosis.
10.4048/jbc.2011.14.4.308
- Author:
Soo Youn BAE
1
;
Min Young CHOI
;
Dong Hui CHO
;
Jeong Eon LEE
;
Seok Jin NAM
;
Jung Hyun YANG
Author Information
1. Department of Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Adenocarcinoma;
Breast;
Invasive ductal carcinoma;
Mucinous;
Prognosis
- MeSH:
Adenocarcinoma;
Adenocarcinoma, Mucinous;
Animals;
Breast;
Chemotherapy, Adjuvant;
Disease-Free Survival;
Lymph Nodes;
Mammary Neoplasms, Animal;
Mucins;
Multivariate Analysis;
Prognosis;
Retrospective Studies
- From:Journal of Breast Cancer
2011;14(4):308-313
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Mucinous carcinoma (MC) of the breast is a rare histologic type of mammary neoplasm. The objective of this study was to evaluate the long-term disease-free survival (DFS) and overall survival (OS) of MC. METHODS: We conducted a retrospective analysis of all MC cases reported to a database between 1994 and 2010. Clinicopathological characteristics and survival of 268 MC cases were reviewed and compared with 2,455 invasive ductal carcinoma-not otherwise specified (IDC-NOS) cases. RESULTS: The MC cases were of a younger age, involved less lymph nodes, lower stage, more expression of hormonal receptors, and less HER2 overexpression compared to the IDC-NOS cases. The 5-year DFS rate for MC was 95.2% compared to 92.0% for IDC-NOS. The 5-year OS rate for MC was 98.9% compared to 94.9% for IDC-NOS. Multivariate analysis using Cox regression revealed that the mucinous type was a significant prognostic factor for DFS with lower nodal status (N stage) and hormonal therapy. For OS, only N stage was the most significant prognostic factor followed by adjuvant chemotherapy and adjuvant hormonal therapy. CONCLUSION: MC was shown to be associated with a better DFS than IDC-NOS, but it had a similar OS. Nodal status and adjuvant therapy appear to be more significant predictors of prognosis than histologic subtype.
